Nightstar Therapeutics (NASDAQ: NITE) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Nightstar Therapeutics to related businesses based on the strength of its dividends, profitability, valuation, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Nightstar Therapeutics and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nightstar Therapeutics 0 0 4 0 3.00
Nightstar Therapeutics Competitors 859 3211 11651 231 2.71

Nightstar Therapeutics currently has a consensus price target of $24.75, suggesting a potential upside of 66.33%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.66%. Given Nightstar Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Nightstar Therapeutics is more favorable than its competitors.


This table compares Nightstar Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nightstar Therapeutics N/A N/A N/A
Nightstar Therapeutics Competitors -5,311.45% -218.34% -39.53%

Insider & Institutional Ownership

27.1% of Nightstar Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Nightstar Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Nightstar Therapeutics N/A N/A -29.76
Nightstar Therapeutics Competitors $284.28 million $33.78 million 83.08

Nightstar Therapeutics’ competitors have higher revenue and earnings than Nightstar Therapeutics. Nightstar Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


Nightstar Therapeutics beats its competitors on 6 of the 10 factors compared.

About Nightstar Therapeutics

Nightstar Therapeutics PLC, formerly Nightstar Therapeutics Limited, is a clinical-stage gene therapy company. The Company is focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. The Company is developing a pipeline of proprietary product candidates that are designed to substantially modify or halt the progression of inherited retinal diseases. The Company’s lead product candidate, NSR-REP1, for the treatment of choroideremia, or CHM, is entering Phase III clinical development. The Company is also conducting a Phase I/II clinical trial with its second product candidate, NSR-RPGR, for the treatment of X-linked retinitis pigmentosa, or XLRP. The Company’s third product candidate, NSR-BEST1, is in preclinical development for the treatment of Best vitelliform macular dystrophy, or Best disease.

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with's FREE daily email newsletter.